Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes. - 2Was This Driver Simply Having A great time Or Behaving Like An Ass?
- 3Timex Gives Its Classic Affordable Field Watch a Tactical, Milspec Makeover
- 4Which Countries Would Suffer Most in a Global Energy Shutdown? This Study Has Answers
- 55 Breakout Stars in Ongoing television Series
- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- Embracing Practical Living and Ecological Protection
- IDF destroys regime's missile, sea mine production site in Yazd amid nationwide airstrikes
- Death toll from floods in Afghanistan rises to 61
- A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024
- Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- No respite for German economy as experts slash forecast over Iran war
- Sunken warship found off Danish coast after 225 years in ‘remarkable’ discovery
